Cochrane review links pharma gifts to inappropriate prescribing and higher costs

A sweeping analysis of nearly a century of research has arrived at a conclusion that feels both obvious and damning: when pharmaceutical companies give doctors gifts, pay for their meals, cover their travel to conferences, or offer them consulting fees, those doctors tend to prescribe differently—and not in ways that benefit patients.

The Cochrane Collaboration, an independent organization that synthesizes medical research, published the findings on October 9, 2026, after examining 93 separate studies of how pharmaceutical promotion influences prescribing behavior. The scope was substantial: 82 of those studies came from the United States, where drug company payments to physicians are publicly tracked and disclosed, while 11 came from the European Union or the UK. What emerged from this body of work was a pattern consistent enough to warrant serious concern.

When researchers looked specifically at the 62 studies that examined gifts and payments—everything from food and beverages to travel reimbursement to conference sponsorships—they found something striking in 10 of those studies. Those studies, which collectively tracked the prescribing patterns of 2.9 million clinicians, showed that doctors who received gifts or payments prescribed less appropriately than those who received none or fewer such benefits. The difference was measurable and significant. Beyond appropriateness, the volume of prescribing itself increased. Thirty-nine studies covering 3.9 million prescribers documented this rise in prescription quantity. And when researchers examined the financial impact, 25 studies tracking 2.5 million prescribers found that gifts and payments were likely associated with higher overall prescribing costs.

What makes this finding particularly troubling is the mechanism at work. Piotr Ozieranski, a researcher at the University of Bath who studies the intersection of pharmaceutical industry and clinical practice, explained that the risk is not conscious corruption—doctors are not knowingly trading prescriptions for free lunches. Rather, the relationship becomes normalized. Social bonds form. An unconscious sense of obligation to reciprocate takes root, subtle enough that clinicians may not recognize it as compromising their judgment, yet powerful enough to shift how they write prescriptions. The result is medication use that is less appropriate, more frequent, and more expensive, all without the prescriber experiencing themselves as having been influenced.

The UK presents a particular puzzle within this landscape. Of the 62 studies examining gifts and payments and their link to prescribing appropriateness, not a single one was conducted in Britain. This absence of evidence is not evidence of absence, Ozieranski cautioned. The UK operates under a voluntary system of self-regulation, allowing pharmaceutical companies to manage their own disclosures rather than submitting to mandatory public reporting like the United States requires. The upcoming government guidance on drug company payment disclosure, he noted, is unlikely to establish the kind of data infrastructure that would make such research possible—or that would enable regulators to enforce stronger conflict-of-interest policies. You cannot regulate what you cannot see.

The pharmaceutical industry's response emphasized existing safeguards. The Association of the British Pharmaceutical Industry pointed out that gifts to healthcare professionals are prohibited under their code of practice, that hospitality is subject to strict standards and reporting, and that NICE guidance and local formulary restrictions already shape prescribing decisions. They cited research from 2024 suggesting that hospitals engaging in industry partnerships were two-and-a-half times more likely to follow NICE recommendations for clinically and cost-effective medicines. Yet this defense does not address the core finding of the Cochrane review: that even within regulated environments, the relationship between industry and prescriber appears to influence prescribing in ways that diverge from what evidence supports.

The human cost sits beneath all of this. Patients receive medications that may be inappropriate for their conditions, or more expensive alternatives when cheaper options would work equally well, or prescriptions they may not need at all. The Cochrane authors concluded that the evidence across all types of pharmaceutical promotion—advertising, education, gifts, samples, and the policies meant to govern them—raises strong concerns about how industry relationships shape clinical decision-making. They called for conflict-of-interest policies robust enough to reduce clinicians' exposure to promotional interactions, both during their training and throughout their practice. Whether such policies can take hold in a system built on voluntary compliance remains an open question.